8月5日 - ** DaVita(DVA.N)股价在盘前交易中下跌4.4%,至218美元
** 这家透析服务提供商周二晚间公布财报 (link),显示第二季度每例治疗的收入从上年同期的417.59美元降至415.87美元
** 重申了2026年经调整每股收益预期为14.10美元至15.20美元。据LSEG汇编的数据,分析师平均预期为14.82美元
** 第二季度每股盈利4.02美元,高于市场预期的3.88美元
** 截至上一交易日收盘,该股年内涨幅已达一倍
8月5日 - ** DaVita(DVA.N)股价在盘前交易中下跌4.4%,至218美元
** 这家透析服务提供商周二晚间公布财报 (link),显示第二季度每例治疗的收入从上年同期的417.59美元降至415.87美元
** 重申了2026年经调整每股收益预期为14.10美元至15.20美元。据LSEG汇编的数据,分析师平均预期为14.82美元
** 第二季度每股盈利4.02美元,高于市场预期的3.88美元
** 截至上一交易日收盘,该股年内涨幅已达一倍
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.